Can a Copper-Binding drug shrink an overgrown heart?

NCT ID NCT04706429

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 29 times

Summary

This study tested a drug called trientine in 154 adults with hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick. Participants took either trientine or a placebo daily for 12 months. The goal was to see if the drug could reduce heart muscle thickness, improve exercise ability, and lower abnormal heart rhythms. The study also explored how trientine works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Liverpool Heart and Chester Hospital NHS Foundation Trust

    Liverpool, L14 3PE, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, M23 9LT, United Kingdom

  • NHS Grampian

    Aberdeen, AB25 2ZN, United Kingdom

  • Northumbria Healthcare NHS Foundation Trust

    North Shields, NE29 8NH, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, OX3 9DU, United Kingdom

  • Royal Brompton and Harefield NHS Foundation Trust

    London, SW3 6NP, United Kingdom

  • University Hospitals of Leicester NHS Foundation Trust

    Leicester, LE3 9QP, United Kingdom

Conditions

Explore the condition pages connected to this study.